Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Pharmacological Reviews
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Pharmacological Reviews

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit Pharm Rev on Facebook
  • Follow Pharm Rev on Twitter
  • Follow ASPET on LinkedIn
Review ArticleReview Article
Open Access

A Practical Review of Proteasome Pharmacology

Tiffany A. Thibaudeau and David M. Smith
Qiang Ma, ASSOCIATE EDITOR
Pharmacological Reviews April 2019, 71 (2) 170-197; DOI: https://doi.org/10.1124/pr.117.015370
Tiffany A. Thibaudeau
Department of Biochemistry, West Virginia University School of Medicine, Morgantown, West Virginia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David M. Smith
Department of Biochemistry, West Virginia University School of Medicine, Morgantown, West Virginia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qiang Ma
Roles: ASSOCIATE EDITOR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    The ubiquitin proteasome pathway. (A) Simplified model of the ubiquitin conjugation system. (B) Primary steps involved in ubiquitinated substrate processing by the 26S proteasome.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Proteasome structure and function. (A) Structures (PDB 4r3o) and cartoon representation of 20S proteasome, highlighting the different β-subunit combinations found in tissue-specific proteasomes discussed in the text. (B) Structure of the 26S proteasome in complex with Ubp6 (PDB 5a5b). A cross-section of 20S proteasome reveals the C terminus of Rpt5 ATPase (dark orange) positioned in the inter-α-subunit pocket (asterisk). Proteolytic sites are marked with yellow stars. Labeled 19S subunits are discussed in the text. (C) 20S proteasomes (blue and gray) complexed with regulatory caps: PA28 homolog PA26 (PDB 1fnt), 19S (PDB 5gjr), and PA200 yeast homolog Blm10 (PDB 4v7o). 19S ATPases are dark orange, and non-ATPase subunits are light orange. PDB, Protein Data Bank.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Examples of cellular functions that depend on proteasome function. Important pathways dependent on proteasome function and exemplar substrates. Bax, bcl-2-like protein 4; Bim, bcl-2-like protein 11; Cdk, cyclin-dependent kinase; Drp1, dynamin-1-like protein; ERAD, endoplasmic-reticulum-associated protein degradation; E2F-1, target of retinoblastoma protein; Fis1, mitochondrial fission 1 protein; GABA, gamma-aminobutyric acid; JNK, C-Jun-amino-terminal kinase; Mfn, mitofusin; MHC-I, major histocompatibility complex-I; Miro, mitochondrial Rho GTPase; NF-κB, nuclear factor–κB; PKA, protein kinase A; PSD-95, postsynaptic density protein 95; Topo II, type II topoisomerase; Wnt, wingless-type.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Proteasome inhibitors and the β5 binding site. (A) Chemical structures of proteasome inhibitors that are FDA approved and/or are in clinical trials with pharmacophores shown in red. For ixazomib, the orally bioavailable prodrug (MLN9708) is shown, with the biologically active metabolite (MLN2238) highlighted in black and red for clarity. (B) X-ray crystallography structures of human 20S proteasomes in complex with carfilzomib (PDB 4r67), bortezomib (PDB 5lf3), and ixazomib (PDB 5lf7); yeast 20S in complex with marizomib (PDB 2fak); and the cryo-EM structure of human 26S in complex with oprozomib (PDB 5m32). PDB, Protein Data Bank.

Tables

  • Figures
    • View popup
    TABLE 1

    Fluorogenic peptides

    SubunitPreferenceSubstrate
    β1AcidicAc-nLPnLD-amc
    Z-LLE-amc
    β1iHydrophobicAc-PAL-amca
    β2BasicBoc-LRR-amc
    Ac-RLR-amc
    β2iBasicNot applicableb
    β5HydrophobicSuc-LLVY-amc
    Ac-WLA-amc
    β5iHydrophobicAc-ANW-amca
    • Ac-nLPnLD-aminoluciferin, N-acetyl-norleucinal-proline-norleucinal-aspartate-amc; Boc-LRR, tert-butoxycarbonyl-leucine-arginine-arginine.

    • ↵a These substrates differentiate between β5 and β5i activity.

    • ↵b Substrates specific for β2i have not been developed to date.

    • View popup
    TABLE 2

    Experimental pitfalls

    Experimental variablesPitfall
    Buffer
     ATP and magnesiumStability of the 26S complex is dependent on a high ATP/ADP ratio. For monitoring 26S activity, an adequate amount of ATP and MgCl2 in a 1:5 ratio (we typically use 2 and 10 mM, respectively) should be present in all buffers to maintain the stability of the 26S proteasome complex. At the same time, the levels of ADP should be kept at a minimum
     GlycerolGlycerol in the buffer stabilizes and maintains the closed, latent gate. Typically, purification buffers for proteasomes contain 10% glycerol, and assay buffers contain 5%
     SDSAddition of 0.02% SDS to assay buffer mildly stimulates opening of the latent 20S gate
    Proteasome populationProteasomes are present as individual 20S particles and 26S particles (singly caped 20S-19S and doubly capped 19S-20S-19S). The 26S complex can dissociate into the 19S and 20S constituents over time, after a freeze/thaw, or in response to buffer condition changes
    When performing experiments with purified 26S proteasomes, it is important to determine the ratio of intact 26S and free 20S proteasomes. This is commonly accomplished by native PAGE electrophoresis as described in the text
    MicroplateThe type of microplate (e.g., untreated vs. nonbinding surface treatments, polypropylene vs. polystyrene) can affect the observed activity. Some substrates (e.g., GFP) interact with and “stick” to untreated plate surfaces. Some compounds or small substrates may bind to the plate surface and reduce the effective concentration in the assay. It is worthwhile to confirm results with new compounds or substrates by using two or more types of plates. Bovine serum albumin can be included in the buffer to prevent nonspecific binding to the plate
    Proteasome gating Experiments probing the role/regulation of the proteasome gate might be facilitated by using the “open-gate” 20S mutant, α3ΔN
    Suc-LLVY-amc has been shown to mildly stimulate gate opening, so another substrate (e.g., Ac-nLPnLD-amc) should be used in conjunction
    • View popup
    TABLE 3

    Cellular proteasome substrates

    SubstrateUb/PathwayLocalizationt1/2Reference
    GFPuYes/CL1 degron30 minBence et al. (2001)
     NLS-GFPuYes/CL1 degronNuclear60 minBennett et al. (2005)
     NES-GFPuYes/CL1 degronCytosolic60 minBennett et al. (2005)
     PSD95-GFPuYes/CL1 degronPostsynapticNDWang et al. (2008)
     SNAP25-GFPuYes/CL1 degronPresynapticNDWang et al. (2008)
    TCR-α–GFPYes/ERADNDDeLaBarre et al. (2006)
    Ub-M-GFPYes/“normal”“Stable”Dantuma et al. (2000)
    Ub-R-GFPYes/N-end rule“Short”Dantuma et al. (2000)
    UbG76V-GFPYes/UFD“Short”Dantuma et al. (2000)
    UbG76V-dendra2Yes/UFDNDHamer et al. (2010)
    GFP-ODCNo2 hLi et al. (1998)
    • M, methionine; ND, not determined; NES, nuclear export signal; NLS, nuclear localization signal; PSD95, postsynaptic density 95; R, arginine; SNAP25, synaptosomal-associated protein 25; t1/2, in vivo half-life; TCR-α, T-cell receptor α chain.

    • View popup
    TABLE 4

    Proteasome inhibitors in clinical testing

    InhibitorClassIC50 In Vitro Peptidase ActivityHalf-LifeRouteBindingReference
    CT-LC-LT-L
    nMmin
    BortezomibBoronate7.953590110i.v./s.c.Slowly reversibleCauhan et al. (2005)
    CarfilzomibEpoxyketone624003600<30i.v.IrreversibleKuhn et al. (2007)
    IxazomibBoronate3.431350018p.o.ReversibleCauhan et al. (2005), Kupperman et al. (2010)
    Marizomibβ-lactone3.54302810–15i.v.IrreversibleFeling et al. (2003)
    OprozomibEpoxyketone36 (β5) NDND30–90p.o.IrreversibleZhou et al. (2009), Roccaro et al. (2010)
    82 (β5i)
    • C-L, caspase-like activity (β1); CT-L, chymotrypsin-like activity (β5); ND, not determined; T-L, trypsin-like activity (β2).

PreviousNext
Back to top

In this issue

Pharmacological Reviews: 71 (2)
Pharmacological Reviews
Vol. 71, Issue 2
1 Apr 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Pharmacological Reviews article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A Practical Review of Proteasome Pharmacology
(Your Name) has forwarded a page to you from Pharmacological Reviews
(Your Name) thought you would be interested in this article in Pharmacological Reviews.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Review ArticleReview Article

A Practical Review of Proteasome Pharmacology

Tiffany A. Thibaudeau and David M. Smith
Pharmacological Reviews April 1, 2019, 71 (2) 170-197; DOI: https://doi.org/10.1124/pr.117.015370

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Review ArticleReview Article

A Practical Review of Proteasome Pharmacology

Tiffany A. Thibaudeau and David M. Smith
Pharmacological Reviews April 1, 2019, 71 (2) 170-197; DOI: https://doi.org/10.1124/pr.117.015370
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • I. Introduction
    • II. Proteasome Structure and Function
    • III. Development of Proteasome Inhibitors
    • IV. Methods for Pharmacological Proteasome Research
    • V. Proteasome Inhibitors to Treat Human Disease
    • VI. Novel Proteasome Drug Targets
    • VII. Conclusions
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Hydroxynorketamines Pharmacology
  • Sex-Based Pharmacology
  • Pharmacology of Polymyxins
Show more Review Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Pharmacological Reviews
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacology Research & Perspectives
ISSN 1521-0081 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics